Xarelto Ad’s Benefit Claims Need Renal Caveats, FDA Says
Typography and graphics which highlight benefits but not risks makes a print ad for Xarelto to treat atrial fibrillation misleading, FDA tells Johnson & Johnson in an untitled letter.
Typography and graphics which highlight benefits but not risks makes a print ad for Xarelto to treat atrial fibrillation misleading, FDA tells Johnson & Johnson in an untitled letter.